Subtype
Malignant Peripheral Nervous System Neoplasm
CI-CAN-00001163Explore in graph →
20 active trials3 evidence items
- NCIt
- C4961
Loading cancer entity…
Subtype
CI-CAN-00001163Explore in graph →
Clinical trials
60 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04222413 | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | recruiting | Phase 1 | 116 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07298083 | DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins | recruiting | — | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 336 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05253131 | Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas | recruiting | Phase 2 | 41 | University of Alabama at BirminghamOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05642455 | SPEARHEAD-3 Pediatric Study | recruiting | Phase 1 / Phase 2 | 20 | USWM CT, LLCINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07549022 | Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor | recruiting | Phase 1 / Phase 2 | 17 | Ankit Mangla, MDOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06735820 | Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST(MEKMDM2) | recruiting | Phase 1 / Phase 2 | 45 | AeRang KimOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05985161 | A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03141021 | Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors | recruiting | — | 1,050 | Washington University School of MedicineOTHER | 5 | Mar 9, 2026 | clinicaltrials |
| NCT04872543 | A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) | recruiting | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials